{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:45:38Z","timestamp":1782744338421,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"DOI":"10.1007\/s10585-026-10416-y","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T01:14:55Z","timestamp":1782695695000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety evaluation of TOPAZ-1 and KEYNOTE-966 regimens in metastatic biliary tract cancer: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"43","author":[{"given":"Elsa","family":"Vitale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Maistrello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ciccimarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz Can","family":"Guven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha Koray","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Sabino Marques","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"de Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Scaramuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Delcuratolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oronzo","family":"Brunetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"issue":"1","key":"10416_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/CEJ.0000000000000758","volume":"32","author":"T Makiuchi","year":"2023","unstructured":"Makiuchi T, Sobue T (2023) Descriptive epidemiology of biliary tract cancer incidence and geographic variation in Japan. Eur J Cancer Prev 32(1):2\u20139. https:\/\/doi.org\/10.1097\/CEJ.0000000000000758","journal-title":"Eur J Cancer Prev"},{"issue":"7","key":"10416_CR2","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1002\/ijc.28161","volume":"133","author":"FA Castro","year":"2013","unstructured":"Castro FA, Koshiol J, Hsing AW, Devesa SS (2013) Biliary tract cancer incidence in the United States-demographic and temporal variations by anatomic site. Int J Cancer 133(7):1664\u20131671. https:\/\/doi.org\/10.1002\/ijc.28161","journal-title":"Int J Cancer"},{"issue":"3","key":"10416_CR3","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.cgh.2017.08.017","volume":"16","author":"LA Torre","year":"2018","unstructured":"Torre LA, Siegel RL, Islami F, Bray F, Jemal A (2018) Worldwide burden of and trends in mortality from gallbladder and other biliary tract cancers. Clin Gastroenterol Hepatol 16(3):427\u2013437. https:\/\/doi.org\/10.1016\/j.cgh.2017.08.017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10272","key":"10416_CR4","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2022","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX (2021) Biliary tract cancer. Lancet. 397(10272):428\u2013444. https:\/\/doi.org\/10.1016\/S0140-6736(21)00153-7. PMID: 33516341","journal-title":"Lancet"},{"issue":"1","key":"10416_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","volume":"7","author":"PJ Brindley","year":"2021","unstructured":"Brindley PJ, Bachini M, Ilyas SI, Khan SA, Loukas A, Sirica AE, Teh BT, Wongkham S, Gores GJ, Cholangiocarcinoma (2021) Nat Rev Dis Primers 7(1):65. https:\/\/doi.org\/10.1038\/s41572-021-00300-2 PMID: 34504109; PMCID: PMC9246479","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"10416_CR6","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41571-023-00770-1","volume":"20","author":"SI Ilyas","year":"2023","unstructured":"Ilyas SI, Affo S, Goyal L, Lamarca A, Sapisochin G, Yang JD, Gores GJ (2023) Cholangiocarcinoma - novel biological insights and therapeutic strategies. Nat Rev Clin Oncol 20(7):470\u2013486. https:\/\/doi.org\/10.1038\/s41571-023-00770-1 Epub 2023 May 15. PMID: 37188899; PMCID: PMC10601496","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10416_CR7","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.3390\/cancers15041244","volume":"15","author":"E Mauro","year":"2023","unstructured":"Mauro E, Ferrer-F\u00e0brega J, Sauri T, Soler A, Cobo A, Burrel M, Iserte G, Forner A (2023) New challenges in the management of cholangiocarcinoma: the role of liver transplantation, locoregional therapies, and systemic therapy. Cancers (Basel) 15(4):1244. https:\/\/doi.org\/10.3390\/cancers15041244 PMID: 36831586; PMCID: PMC9953927","journal-title":"Cancers (Basel)"},{"issue":"Suppl 15","key":"10416_CR8","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1200\/JCO.2019.37.15_suppl.4079","volume":"37","author":"YJ Bang","year":"2019","unstructured":"Bang YJ, Ueno M, Malka D et al (2019) Pembrolizumab (pembro) for advanced biliary adenocarcinoma: results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies [Abstract]. J Clin Oncol 37(Suppl 15):4079","journal-title":"J Clin Oncol"},{"key":"10416_CR9","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","volume":"7","author":"D-Y Oh","year":"2022","unstructured":"Oh D-Y, Lee K-H, Lee D-W et al (2022) Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single centre, phase 2 study. Lancet Gastroenterol Hepatol 7:522\u2013532. https:\/\/doi.org\/10.1016\/S2468-1253(22)00043-7","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10416_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.intimp.2013.12.022","volume":"19","author":"Q Pei","year":"2014","unstructured":"Pei Q, Pan J, Zhu H et al (2014) Gemcitabine-treated pancreatic cancer cell medium induces the specific CTL antitumor activity by stimu lating the maturation of dendritic cells. Int Immunopharmacol 19:10\u201316. https:\/\/doi.org\/10.1016\/j.intimp.2013.12.022","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10416_CR11","doi-asserted-by":"publisher","first-page":"28309","DOI":"10.1038\/s41598-024-71746-z","volume":"14","author":"E Vitale","year":"2024","unstructured":"Vitale E, Rizzo A, Maistrello L, Guven DC, Massafra R, Mollica V, Monteiro FSM, Santoni M, Massari F (2024) Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis. Sci Rep 14(1):28309. https:\/\/doi.org\/10.1038\/s41598-024-71746-z PMID: 39550353; PMCID: PMC11569249","journal-title":"Sci Rep"},{"key":"10416_CR12","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u0131guez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078\u20132092. https:\/\/doi.org\/10.1056\/NEJMoa1801005","journal-title":"N Engl J Med"},{"key":"10416_CR13","doi-asserted-by":"publisher","unstructured":"Oh DY, Ruth He A, Qin S, Chen LT, Okusaka T, Vogel A, Kim JW, Suksombooncharoen T, Ah Lee M, Kitano M, Burris H, Bouattour M, Tanasanvimon S, McNamara MG, Zaucha R, Avallone A, Tan B, Cundom J, Lee CK, Takahashi H, Ikeda M, Chen JS, Wang J, Makowsky M, Rokutanda N, He P, Kurland JF, Cohen G, Valle JW (2022) Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid. 1(8): EVIDoa2200015. https:\/\/doi.org\/10.1056\/EVIDoa2200015. Epub 2022 Jun 1. PMID: 38319896","DOI":"10.1056\/EVIDoa2200015"},{"key":"10416_CR14","doi-asserted-by":"publisher","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Kl\u00fcmpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel A (2023) KEYNOTE-966 Investigators. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 401(10391):1853\u20131865. doi: 10.1016\/S0140-6736(23)00727-4. Epub 2023 Apr 16. Erratum in: Lancet. 2023;402(10406):964. https:\/\/doi.org\/10.1016\/S0140-6736(23)01904-9. Erratum in: Lancet. 2024;403(10432):1140. doi: 10.1016\/S0140-6736(24)00545-2. PMID: 37075781","DOI":"10.1016\/S0140-6736(23)01904-9"},{"key":"10416_CR15","doi-asserted-by":"publisher","first-page":"1409132","DOI":"10.3389\/fonc.2024.1409132","volume":"14","author":"E Vitale","year":"2024","unstructured":"Vitale E, Rizzo A, Maistrello L, Nardulli P, Talienti T, Quaresmini D, De Summa S, Massafra R, Silvestris N, Brunetti O (2024) The role of immune checkpoint inhibitors in the first-line treatment for patients with advanced biliary tract cancer: a systematic review and meta-analysis of randomized trials. Front Oncol 14:1409132. https:\/\/doi.org\/10.3389\/fonc.2024.1409132","journal-title":"Front Oncol"},{"issue":"2","key":"10416_CR16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jhep.2015.10.006","volume":"64","author":"European Association for the Study of the Liver","year":"2016","unstructured":"European Association for the Study of the Liver (2016) EASL Clinical practice guidelines: liver transplantation. J Hepatol 64(2):433\u2013485. https:\/\/doi.org\/10.1016\/j.jhep.2015.10.006 Epub 2015 Nov 17. PMID: 26597456","journal-title":"J Hepatol"},{"issue":"6","key":"10416_CR17","doi-asserted-by":"publisher","first-page":"108489","DOI":"10.1016\/j.ejso.2024.108489","volume":"51","author":"K S\u00f8reide","year":"2025","unstructured":"S\u00f8reide K, Dopazo C, Berrevoet F, Carrion-Alvarez L, Diaz-Nieto R, Andersson B, St\u00e4ttner S (2025) joint ESSO-EAHPBA-UEMS core curriculum working group. Biliary tract cancer. Eur J Surg Oncol 51(6):108489. https:\/\/doi.org\/10.1016\/j.ejso.2024.108489 Epub 2024 Jun 15. PMID: 38902180","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"10416_CR18","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11523-024-01060-1","volume":"19","author":"M Rimini","year":"2024","unstructured":"Rimini M, Masi G, Lonardi S, Nichetti F, Pressiani T, Lavacchi D, Jessica L, Giordano G, Scartozzi M, Tamburini E, Pastorino A, Rapposelli IG, Daniele B, Martinelli E, Garajova I, Aprile G, Schirripa M, Formica V, Salani F, Winchler C, Bergamo F, Balsano R, Gusmaroli E, Lorenzo A, Landriscina M, Pretta A, Toma I, Pirrone C, Diana A, Leone F, Brunetti O, Brandi G, Garattini SK, Satolli MA, Rossari F, Fornaro L, Niger M, Zanuso V, De Rosa A, Ratti F, Aldrighetti L, De Braud F, Foti S, Rizzato MD, Vivaldi C, Stefano C, Rimassa L, Antonuzzo L, Casadei-Gardini A (2024) Durvalumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin in biliary tract cancer: a real-world retrospective, multicenter study. Target Oncol 19(3):359\u2013370. https:\/\/doi.org\/10.1007\/s11523-024-01060-1 Epub 2024 May 1. PMID: 38691295","journal-title":"Target Oncol"},{"key":"10416_CR19","doi-asserted-by":"publisher","unstructured":"Mauro E, Forner A (2023) Immunotherapy in biliary tract cancer: the race has begun!, Liver Int. 43(8):1620\u20131622. https:\/\/doi.org\/10.1111\/liv.15651. PMID: 37452502","DOI":"10.1111\/liv.15651"},{"key":"10416_CR20","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71 PMID: 33782057; PMCID: PMC8005924","journal-title":"BMJ"},{"key":"10416_CR21","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"10416_CR22","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1002\/sim.8158","volume":"38","author":"O Efthimiou","year":"2019","unstructured":"Efthimiou O, R\u00fccker G, Schwarzer G, Higgins JPT, Egger M, Salanti G (2019) Network meta-analysis of rare events using the Mantel-Haenszel method. Stat Med 38:2992\u20133012. https:\/\/doi.org\/10.1002\/sim.8158","journal-title":"Stat Med"},{"issue":"4","key":"10416_CR23","first-page":"719","volume":"22","author":"N Mantel","year":"1959","unstructured":"Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22(4):719\u2013748","journal-title":"J Natl Cancer Inst"},{"key":"10416_CR24","unstructured":"Deeks JJ, Higgins JP, Altman DG Analysing data and undertaking meta-analyses. In Cochrane Handbook for Systematic Reviews of Interventions (eds J.P.T)"},{"key":"10416_CR25","doi-asserted-by":"publisher","unstructured":"Higgins J, Thomas J, Chandler M, Cumpston T, Li MJ, Page, Welch VA (2019) https:\/\/doi.org\/10.1002\/9781119536604.ch10; Higgins JP, Green S. (Eds.). Cochrane handbook for systematic reviews of interventions, 2008","DOI":"10.1002\/9781119536604.ch10"},{"key":"10416_CR26","unstructured":"Higgins JPT, Green S (2022) Chapter 10: analysing data and undertaking meta-analyses. In J. P. T. Higgins & S. Green (Eds.), Cochrane Handbook for Systematic Reviews of Interventions (2nd ed.)"},{"key":"10416_CR27","doi-asserted-by":"crossref","unstructured":"John, Wiley, Sons; Borenstein M, Hedges LV, Higgins JPT, Rothstein HR (2021) Introduction to meta-analysis, 2nd edn. Wiley","DOI":"10.1002\/9781119558378"},{"issue":"7300","key":"10416_CR28","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1136\/bmj.322.7300.1479","volume":"322","author":"S Lewis","year":"2001","unstructured":"Lewis S, Clarke M (2001) Forest plots: trying to see the wood and the trees. BMJ 322(7300):1479\u20131480. https:\/\/doi.org\/10.1136\/bmj.322.7300.1479","journal-title":"BMJ"},{"issue":"3","key":"10416_CR29","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3390\/cancers17030555","volume":"17","author":"TE Bousou","year":"2025","unstructured":"Bousou TE, Sarantis P, Anastasiou IA, Trifylli EM, Liapopoulos D, Korakaki D, Koustas E, Katsimpoulas M, Karamouzis MV (2025) Biomarkers for the evaluation of immunotherapy in patients with cholangiocarcinoma. Cancers (Basel) 17(3):555. https:\/\/doi.org\/10.3390\/cancers17030555 PMID: 39941920; PMCID: PMC11817672","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10416_CR30","doi-asserted-by":"publisher","first-page":"e13513","DOI":"10.1111\/cpr.13513","volume":"56","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Gu Q, Zhu L, Zhang S, Wu H, Pu X, Jiang C, Chen J (2023) High endothelial venule is a prognostic immune-related biomarker in patients with resected intrahepatic cholangiocarcinoma. Cell Prolif 56(12):e13513. https:\/\/doi.org\/10.1111\/cpr.13513Epub 2023 Jul 3. PMID: 37401015; PMCID: PMC10693183","journal-title":"Cell Prolif"},{"key":"10416_CR31","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00286","author":"AL Heeke","year":"2018","unstructured":"Heeke AL, Pishvaian MJ, Lynce F, Xiu J, Brody JR, Chen WJ, Baker TM, Marshall JL, Isaacs C (2018) Prevalence of homologous recombination-related gene mutations across multiple cancer types. JCO Precis Oncol. https:\/\/doi.org\/10.1200\/PO.17.00286 Epub 2018 Jul 23. PMID: 30234181; PMCID: PMC6139373 2018:PO.17.00286","journal-title":"JCO Precis Oncol"},{"issue":"17","key":"10416_CR32","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.3390\/cancers15174217","volume":"15","author":"H Bourien","year":"2023","unstructured":"Bourien H, Pircher CC, Guiu B, Lamarca A, Valle JW, Niger M, Edeline J (2023) Locoregional treatment in intrahepatic cholangiocarcinoma: Which treatment for which patient? Cancers (Basel) 15(17):4217. https:\/\/doi.org\/10.3390\/cancers15174217 PMID: 37686493; PMCID: PMC10486617","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10416_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2022.0611","volume":"8","author":"G Terrero","year":"2022","unstructured":"Terrero G, Datta J, Dennison J, Sussman DA, Lohse I, Merchant NB, Hosein PJ (2022) Ipilimumab\/Nivolumab therapy in patients with metastatic pancreatic or biliary cancer with homologous recombination deficiency pathogenic germline variants. JAMA Oncol 8(6):1\u20133 PMID: 35446342; PMCID: PMC9026238","journal-title":"JAMA Oncol"},{"issue":"18","key":"10416_CR34","doi-asserted-by":"publisher","first-page":"10869","DOI":"10.3390\/ijms231810869","volume":"23","author":"G Brandi","year":"2022","unstructured":"Brandi G, Rizzo A (2022) IDH Inhibitors and Immunotherapy for Biliary Tract Cancer: A Marriage of Convenience? Int J Mol Sci 23(18):10869. https:\/\/doi.org\/10.3390\/ijms231810869 PMID: 36142781; PMCID: PMC9503989","journal-title":"Int J Mol Sci"},{"key":"10416_CR35","doi-asserted-by":"publisher","unstructured":"Kalyan A, Khosla H, Kim RD (2022) Immunotherapy in biliary tract cancers: Where are we?, Curr Oncol Rep. 24(12):1821\u20131828. https:\/\/doi.org\/10.1007\/s11912-022-01328-7. Epub 2022 Oct 4. PMID: 36192517","DOI":"10.1007\/s11912-022-01328-7"},{"key":"10416_CR36","doi-asserted-by":"publisher","first-page":"1124482","DOI":"10.3389\/fimmu.2023.1124482","volume":"14","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Wang G, Du L, Zhao J, Pan L, Zhang G, Wang F, Liu R (2023) Case report: persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma. Front Immunol 14:1124482 PMID: 37292215; PMCID: PMC10245386","journal-title":"Front Immunol"},{"issue":"3","key":"10416_CR37","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.soc.2019.02.009","volume":"28","author":"K Sanchez","year":"2019","unstructured":"Sanchez K, Page DB, Urba W (2019) Immunotherapy toxicities. Surg Oncol Clin N Am 28(3):387\u2013401. https:\/\/doi.org\/10.1016\/j.soc.2019.02.009 Epub 2019 Apr 5. PMID: 31079795","journal-title":"Surg Oncol Clin N Am"},{"key":"10416_CR38","doi-asserted-by":"publisher","unstructured":"Kennedy LB, Salama AKS (2020) A review of cancer immunotherapy toxicity. CA Cancer J Clin. 70(2):86\u2013104. https:\/\/doi.org\/10.3322\/caac.21596. Epub 2020 Jan 16. PMID: 31944278","DOI":"10.3322\/caac.21596"},{"issue":"6","key":"10416_CR39","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.chest.2018.08.1048","volume":"154","author":"K Suresh","year":"2018","unstructured":"Suresh K, Naidoo J, Lin CT, Danoff S (2018) Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities. Chest 154(6):1416\u20131423. https:\/\/doi.org\/10.1016\/j.chest.2018.08.1048 Epub 2018 Sep 4. PMID: 30189190; PMCID: PMC6335259","journal-title":"Chest"},{"key":"10416_CR40","doi-asserted-by":"publisher","unstructured":"Simand PF, Baudoux N, K\u00f6ssler T (2023) Immunotherapy and gastrointestinal toxicities. Praxis (Bern 1994). 112(3):172\u2013177. https:\/\/doi.org\/10.1024\/1661-8157\/a003977. PMID: 36855888","DOI":"10.1024\/1661-8157\/a003977"},{"key":"10416_CR41","doi-asserted-by":"publisher","first-page":"1390887","DOI":"10.3389\/fimmu.2024.1390887","volume":"15","author":"TB Madzikatire","year":"2024","unstructured":"Madzikatire TB, Heng S, Gu H, Shan Y, Lin E, Banda J, Debora A, Madziva BA, Bowa MJ, Mudhuri MG, Bwalya C (2024) Real-world outcomes of chemotherapy plus immune checkpoint inhibitors versus chemotherapy alone in advanced, unresectable, and recurrent intrahepatic cholangiocarcinoma. Front Immunol 15:1390887. https:\/\/doi.org\/10.3389\/fimmu.2024.1390887 PMID: 38846939; PMCID: PMC11153733","journal-title":"Front Immunol"},{"issue":"8","key":"10416_CR42","doi-asserted-by":"publisher","first-page":"541","DOI":"10.7326\/M19-3286","volume":"172","author":"DE Kloecker","year":"2020","unstructured":"Kloecker DE, Davies MJ, Khunti K, Zaccardi F (2020) Uses and limitations of the restricted mean survival time: illustrative examples from cardiovascular outcomes and mortality trials in type 2 diabetes. Ann Intern Med 172(8):541\u2013552. https:\/\/doi.org\/10.7326\/M19-3286 Epub 2020 Mar 24. PMID: 32203984","journal-title":"Ann Intern Med"},{"key":"10416_CR43","doi-asserted-by":"publisher","unstructured":"Burris HA 3rd, Okusaka T, Vogel A, Lee MA, Takahashi H, Breder V, Blanc JF, Li J, Bachini M, \u017botkiewicz M, Abraham J, Patel N, Wang J, Ali M, Rokutanda N, Cohen G, Oh DY (2024) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 25(5):626\u2013635. https:\/\/doi.org\/10.1016\/S1470-2045(24)00082-2. PMID: 38697156","DOI":"10.1016\/S1470-2045(24)00082-2"},{"issue":"7","key":"10416_CR44","doi-asserted-by":"publisher","first-page":"oyaf148","DOI":"10.1093\/oncolo\/oyaf148","volume":"30","author":"L Antonuzzo","year":"2025","unstructured":"Antonuzzo L, Takahashi H, Park JO, Sookprasert A, Gillmore R, Yang SS, Cundom J, Petrova M, Vaccaro G, Holmblad M, \u017botkiewicz M, Wang J, Rokutanda N, Oh DY (2025) Immune-mediated adverse events in the randomized phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. Oncologist 30(7):oyaf148. https:\/\/doi.org\/10.1093\/oncolo\/oyaf148 PMID: 40622010; PMCID: PMC12230790","journal-title":"Oncologist"},{"issue":"2","key":"10416_CR45","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40268-024-00478-2","volume":"24","author":"S Bellino","year":"2024","unstructured":"Bellino S, La Salvia A (2024) The importance of patient reported outcomes in oncology clinical trials and clinical practice to inform regulatory and healthcare decision-making. Drugs R D 24(2):123\u2013127. https:\/\/doi.org\/10.1007\/s40268-024-00478-2 Epub 2024 Jul 18. PMID: 39023849; PMCID: PMC11315859","journal-title":"Drugs R D"}],"container-title":["Clinical & Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-026-10416-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-026-10416-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-026-10416-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:04:11Z","timestamp":1782741851000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-026-10416-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":45,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["10416"],"URL":"https:\/\/doi.org\/10.1007\/s10585-026-10416-y","relation":{},"ISSN":["1573-7276"],"issn-type":[{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"24 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FSMM has received research support provided by MSD and Foundation Medicine. Honoraria from Janssen, Ipsen, BMS, Novartis, AstraZeneca, Bayer, Astellas and MSD. Travel expenses by Novartis, Bayer, ADIUM, Merck and Johson & Johson. Consulting or Advisory Role from Novartis. Ownership: BIO, Brazilian Information Oncology. All are unrelated to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"33"}}